Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance

The improved efficacy and tolerability of newer antiretroviral drugs, as well as the introduction of long-acting regimens, have prompted more frequent therapy switches in individuals on suppressive antiretroviral therapy (ART). For these individuals, the assessment of HIV drug resistance using DNA from peripheral blood lymphocytes has become increasingly popular. However, compared with HIV RNA-based analyses, implementation of HIV DNA testing as an alternative approach in clinical care requires new documented quality-assessment procedures and clinical validation. Furthermore, the use of HIV DNA to assess drug resistance has some distinct technical and biologic challenges that are relevant to the clinical management of people with HIV. This Viewpoint article addresses the issues relevant to clinical virologists and treating physicians for the interpretation of drug-resistance testing or subtype assessment based on DNA analysis, when HIV RNA genotypic assessment is not possible.

Authors

Institutions

Publication Details

Journal
Clinical Infectious Diseases
Published
2025-04-02
DOI
https://doi.org/10.1093/cid/ciaf161
Citations
12
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
12.44
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance

Vincent Cálvez, Donna M. Jacobsen, Annemarie M. J. Wensing, Charlotte Charpentier et al.
12 citations
Clinical Infectious Diseases
HIV Research and Treatment
12.44
article

Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance

Vincent Cálvez, Donna M. Jacobsen, Annemarie M. J. Wensing, Charlotte Charpentier, Huldrych F. Günthard, Robert W. Shafer, Francesca Ceccherini‐Silberstein, Douglas D. Richman, Roger Paredes
article en
12 citations

Abstract

The improved efficacy and tolerability of newer antiretroviral drugs, as well as the introduction of long-acting regimens, have prompted more frequent therapy switches in individuals on suppressive antiretroviral therapy (ART). For these individuals, the assessment of HIV drug resistance using DNA from peripheral blood lymphocytes has become increasingly popular. However, compared with HIV RNA-based analyses, implementation of HIV DNA testing as an alternative approach in clinical care requires new documented quality-assessment procedures and clinical validation. Furthermore, the use of HIV DNA to assess drug resistance has some distinct technical and biologic challenges that are relevant to the clinical management of people with HIV. This Viewpoint article addresses the issues relevant to clinical virologists and treating physicians for the interpretation of drug-resistance testing or subtype assessment based on DNA analysis, when HIV RNA genotypic assessment is not possible.

Clinical Infectious DiseasesVol. 81(4)
University of Rome Tor Vergata (IT), Inserm (FR), University of San Diego (US), University of the Witwatersrand (ZA), University of Zurich (CH), Université Paris Cité (FR), University Medical Center Utrecht (NL), University of California San Diego (US), Sorbonne Université (FR), Assistance Publique – Hôpitaux de Paris (FR), San Francisco Medical Society (US), University Hospital of Zurich (CH), Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR), Hôpital Bichat-Claude-Bernard (FR), Hospital Universitari Germans Trias i Pujol (ES), Universitat Politècnica de Catalunya (ES), Stanford University (US)
Good health and well-being
Openalex Percentile: Top 1%
HIV Research and Treatment
12.44
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.